Company will add expertise in TLR modulator R&D.
Telormedix has joined the collaborative research program targeting novel mechanisms of resolution in inflammation called TIMER. The project is funded with €3 million (roughly $3.95 million) from the EU to establish a robust collaboration with Brazil.
TIMER comprises a team of European universities and research institutions as well as Brazilian groups. Industry partners include Merck Serono and now Telormedix, which will promote translational research. Telormedix’ contribution to the project, coordinated by Alcide Barberis, head of research and collaborations, will draw on its expertise in the field of toll-like receptors (TLRs) modulators.
Telormedix’ lead product, TMX-101, recently entered a Phase I/II trial for the treatment of nonmuscle invasive bladder cancer (NMIBC). In addition, Telormedix is developing two TLR7-targeted molecules, TMX-201 and TMX-202, as a vaccine adjuvant. One of these molecules, TMX-202, has recently been selected for preclinical study for the topical treatment of skin cancers and other indications. Telormedix also has an additional programm focused on autoimmune disorders called TMX-30X.
TIMER was launched on January 1 to accelerate the development of novel strategies to fight inflammation. Scientists from nine research partners in four European countries and three research partners in Brazil are working together.
“This is a unique opportunity for European scientists to strengthen ties with Brazilian colleagues addressing central issues related to inflammation, of broad potential in immune-based pathologies,” says Alberto Mantovani, coordinator of TIMER and director of the Istituto Clinico Humanitas in Milan. “The availability of natural resources, models of diseases, original paradigms, and molecular approaches will be conducive to synergistic interactions.”
